Merck’s Ebola vaccine, Ervebo, has been approved for use in four African countries including the Democratic Republic of Congo, and the first licensed doses are expected to be made available in the third quarter of this year.
The approvals in DRC, Burundi, Ghana, and Zambia mean that Merck can stockpile the vaccine and distribute it widely to...







